Bone decay results in $10.5 million verdict 
By:
Correy Stephenson
Published: November 21, 2012
Tags: bone decay, breast cancer, drug litigation, Hurricane Sandy, necrosis, Novartis, Zometa
A federal jury in New York weathered Hurricane Sandy to award a plaintiff almost $10.5 million after she developed necrosis of the jaw from taking Zometa.
Jury awards $5 million in HRT-breast cancer case
By:
Sylvia Hsieh
Published: September 21, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT, HRT litigation, Pfizer, Prempro, product liability, Provera, Upjohn, Wyeth
A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.
Prempro expert could testify regarding short-term use
Published: July 30, 2012
Tags: breast cancer, Daubert, expert witness, hormone replacement therapy, Prempro, Wyeth
Product liability plaintiffs should have been permitted to introduce expert testimony linking the short-term use of Prempro to a risk of breast cancer, the 8th Circuit has ruled in reversing a summary judgment.
Woman wins $4 million in Prempro breast cancer trial
By:
Sylvia Hsieh
Published: April 27, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT litigation, Pfizer, Prempro, Wyeth
A 65-year-old elementary school principal has won a $4 million verdict in Connecticut federal court against the maker of the menopause drug Prempro for causing her breast cancer.
Prempro plaintiff can’t show causation, District Court rules
Published: March 13, 2012
Tags: breast cancer, causation, failure to warn, hormone replacement therapy, Premarin, Prempro, product liability, Provera, Upjohn, Wyeth
A product liability plaintiff could not show that the alleged failure of pharmaceutical companies to warn about the dangers of their hormone therapy drugs was the proximate cause of her breast cancer, a U.S. District Court in South Carolina has ruled in granting summary judgment.
Jury awards $15M for failure to diagnose breast cancer
By:
Correy Stephenson
Published: February 16, 2012
Tags: breast cancer, misdiagnosis
After a doctor failed to diagnosis a lump in a woman’s breast as cancer, allowing the disease to spread throughout her body and metastasize to her bones, a jury has awarded her $15 million.
Pa. court reinstates $28M punitive award in HRT case
Published: January 10, 2012
Tags: breast cancer, HRT litigation, Premarin, Prempro, product liability, Provera, Upjohn, Wyeth
A $28 million award of punitive damages was not unconstitutionally excessive in a product liability case brought by a woman who contracted breast cancer after taking hormone replacement therapy drugs, a Pennsylvania appellate court has ruled in reversing judgment.
Wyeth’s marketing efforts admissible in Prempro case
Published: January 10, 2012
Tags: breast cancer, HRT litigation, Prempro, product liability, Wyeth
Evidence of Wyeth’s marketing campaign for “off-label” Prempro uses was admissible in a product liability case brought by a woman who contracted breast cancer after taking the drug, a Pennsylvania appellate court has ruled.
Delayed cancer diagnosis leads to $2.65 million verdict
Published: December 21, 2011
Tags: breast cancer, cancer, delayed diagnosis, medical malpractice, medical negligence, mental anguish, Virginia
A Virginia jury has returned a $2.65 million verdict against a radiologist whose admitted negligence led to a delay in the diagnosis of breast cancer for a 54-year-old woman.
Prempro breast cancer cases settle after jury awards $76 million
By:
Sylvia Hsieh
Published: December 15, 2011
Tags: breast cancer, failure to warn, Pennsylvania, Premarin, Prempro, prescription drugs, Provera
After a jury in Philadelphia awarded $76 million in compensatory damages to three women who claimed that the hormone therapy drugs Prempro, Premarin and Provera caused their breast cancer, drug maker Wyeth Pharmaceuticals settled the cases for a confidential amount.
